Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › denosumab

denosumab

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of denosumab

65 trials tracked of denosumab: 34 in phase 3 or 4 and 6 with published results. The most-cited published study has 447 citations.

65Trials tracked
34Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 7 Phase 3 27 Phase 2 22 Phase 1 6 Other / NA 3
  1. Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 447 cited
  2. Phase 3 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed · 344 cited
  3. Phase 3 Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids Completed · 208 cited
  4. Phase 3 Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis Completed · 170 cited
  5. Phase 4 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed · 70 cited
  6. Phase 3 Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND Completed · 3 cited
Show 44 more trials
  1. Phase 4 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Completed
  2. Phase 4 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Completed
  3. Phase 4 Preventing Osteoporosis Using Denosumab Completed
  4. Phase 4 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Completed
  5. Phase 4 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed
  6. Phase 4 Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Completed
  7. Phase 3 Denosumab China Phase III Study Completed
  8. Phase 3 Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Completed
  9. Phase 3 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed
  10. Phase 3 Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy Completed
  11. Phase 3 Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis Completed
  12. Phase 3 A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  13. Phase 3 Denosumab Adherence Preference Satisfaction Study Completed
  14. Phase 3 Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis Completed
  15. Phase 3 A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates Completed
  16. Phase 3 Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer Completed
  17. Phase 3 Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer Completed
  18. Phase 3 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  19. Phase 3 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer Completed
  20. Phase 3 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy Completed
  21. Phase 3 A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab Completed
  22. Phase 3 A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density. Completed
  23. Phase 3 Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy Completed
  24. Phase 3 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. Completed
  25. Phase 3 A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density Completed
  26. Phase 3 Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer Completed
  27. Phase 3 A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis Completed
  28. Phase 3 A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. Completed
  29. Phase 2 Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer Completed
  30. Phase 2 Denosumab and MRI Breast Imaging Completed
  31. Phase 2 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Completed
  32. Phase 2 Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab Completed
  33. Phase 2 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) Completed
  34. Phase 2 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) Completed
  35. Phase 2 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density Completed
  36. Phase 2 Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis Completed
  37. Phase 2 Denosumab for Smoldering Multiple Myeloma Completed
  38. Phase 2 Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis Completed
  39. Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone Completed
  40. Phase 2 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed
  41. Phase 2 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions Completed
  42. Phase 2 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed
  43. Phase 2 Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer Completed
  44. Phase 2 Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant Completed

Showing the 50 most-cited and recently-updated of 65 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation
Orthopedics & Sports Medicine Meta-analysis
Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation Potent bisphosphonates may lower fracture risk after denosumab treatment stops
This meta-analysis of 683 adults with osteoporosis or low bone mass found that potent bisphosphonate therapy significantly reduced incident …
Patients with osteoporosis may have a lower risk of spine fractures when switching to potent bisphosphonates after stopping denosumab.
NEJM Sep 6, 2026
Denosumab reduces morphometric vertebral fracture risk in men with non-metastatic prostate cancer on ADT
Orthopedics & Sports Medicine Meta-analysis
Denosumab reduces morphometric vertebral fracture risk in men with non-metastatic prostate cancer on ADT Denosumab cuts spine fracture risk in prostate cancer
This meta-analysis of 26 RCTs evaluated antiresorptive agents for bone health in men with non-metastatic prostate cancer on ADT. Denosumab s…
Men on hormone therapy for prostate cancer may face fewer spine fractures with denosumab, but other bone drugs showed no clear fracture bene…
Sep 3, 2026
Shared molecular pathways and hub genes link endocrine disorders with periodontitis progression
Neurology Sys. Review
Shared molecular pathways and hub genes link endocrine disorders with periodontitis progression Shared Molecular Pathways Link Endocrine Disorders and Periodontitis
This narrative review synthesizes the molecular mechanisms underlying the crosstalk between endocrine disorders and periodntis. It identifie…
New research identifies shared biological pathways that link endocrine disorders with gum disease, potentially changing how doctors treat bo…
Frontiers Jul 18, 2026
One-time EBRT is as effective as multi-fraction treatments for pain management in malignant bone tumors
Oncology Meta-analysis
One-time EBRT is as effective as multi-fraction treatments for pain management in malignant bone tumors One radiation session works as well as multiple for bone tumor pain
This meta-analysis evaluates the efficacy of radiation and bone-modifying agents for managing pain and preventing skeletal-related events in…
A single radiation session eases bone tumor pain just as well as multiple sessions, a new analysis finds. Bisphosphonates also help.
Frontiers Jul 9, 2026
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates
Drug Pipeline Sys. Review
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates New osteoporosis treatments target bone-eating cells more safely
This narrative review examines emerging therapeutic strategies that target osteoclast fusion and polarization, including DC-STAMP/OC-STAMP n…
Future osteoporosis drugs may work by blocking the fusion of bone-destroying cells, offering a safer alternative to current treatments.
Frontiers Jun 5, 2026
Network meta-analysis compares osteoporosis drugs for bone density in men
Diabetes & Endocrinology Meta-analysis
Network meta-analysis compares osteoporosis drugs for bone density in men Men's Osteoporosis Drugs Work Better on Spines Than Hips
This network meta-analysis of 4,409 men with primary osteoporosis compared six medications. It found significant improvements in bone minera…
• Abaloparatide and teriparatide boost spine bone density most • Helps men with weak bones avoid fractures • Not yet proven to prevent actua…
Frontiers May 8, 2026
Narrative review examines coronary risk and vascular effects of bisphosphonates, denosumab, and romosozumab in osteoporosis
Diabetes & Endocrinology Sys. Review
Narrative review examines coronary risk and vascular effects of bisphosphonates, denosumab, and romosozumab in osteoporosis Osteoporosis drugs show no clear heart risk or benefit
This narrative review evaluates the cardiovascular safety profile of anti-osteoporosis therapies including bisphosphonates, denosumab, and r…
Common osteoporosis drugs don't have a clear effect on heart health, but one newer drug still raises safety questions.
Frontiers Apr 29, 2026
Case report review of VMAT, utidelone, and denosumab in a breast cancer patient with clivus metastasis
Drug Pipeline Sys. Review
Case report review of VMAT, utidelone, and denosumab in a breast cancer patient with clivus metastasis Rare Breast Cancer Skull Case Achieves Long-Term Remission With New Plan
This case report review describes a single breast cancer patient with clivus metastasis treated with volumetric modulated arc therapy (VMAT)…
A rare case of breast cancer spreading to the skull shows long-term remission using a specific drug and radiation plan.
Frontiers Apr 24, 2026
Antiresorptive and Anabolic Agents Improve Bone Microarchitecture in Postmenopausal Women With Type 2 Diabetes: Pilot RCT
Diabetes & Endocrinology RCT
Antiresorptive and Anabolic Agents Improve Bone Microarchitecture in Postmenopausal Women With Type 2 Diabetes: Pilot RCT Diabetes Weakens Bones: One Drug Builds Them Back
This pilot randomized controlled trial evaluated antiresorptive and anabolic agents in 129 postmenopausal women with Type 2 Diabetes.
Building new bone tissue with a specific daily shot works better than just protecting existing bone for women with diabetes.
Apr 22, 2026
Meta-analysis shows perioperative denosumab increases local recurrence in giant cell tumor patients
Oncology Meta-analysis
Meta-analysis shows perioperative denosumab increases local recurrence in giant cell tumor patients A Common Bone Tumor Drug May Raise the Risk of Cancer Coming Back
This meta-analysis evaluated perioperative denosumab in 1,551 patients undergoing surgical management of giant cell tumor.
Taking a common bone tumor drug before and after surgery nearly tripled the chance of the tumor growing back in a new analysis of 1,551 pati…
Apr 18, 2026
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Primary Care & Family Medicine Guideline
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma.
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
Frontiers Apr 16, 2026
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months
Diabetes & Endocrinology Meta-analysis
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months Men Get Osteoporosis Too — and Now We Know Which Drugs Win
This Bayesian network meta-analysis evaluated antiresorptive and anabolic pharmacological interventions in men with osteoporosis.
A new analysis of 18 clinical trials finds that bone-building drugs may outperform bone-preserving drugs for men with osteoporosis, especial…
Frontiers Apr 10, 2026

All denosumab Articles